Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire July 01, 2025 CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of June 26, 2025, the Board of Directors granted Jean-Paul Kress, the Company's Chief […]